Date published: 2026-7-5

1-800-457-3801

SCBT Portrait Logo
Seach Input

B7-H3 Double Nickase Plasmid (h): sc-402032-NIC

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • B7-H3 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
  • Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
  • One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
  • B7-H3 Double Nickase Plasmid (h) and B7-H3 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CD276. One or both designs may be available
  • Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: B7-H3 Antibody (F-11): sc-376769
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    B7-H3 Double Nickase Plasmid (h)

    sc-402032-NIC
    20 µg
    $410.00

    B7-H3 Double Nickase Plasmid (h2)

    sc-402032-NIC-2
    20 µg
    $410.00

    CD276 encodes the immunoregulatory surface glycoprotein B7-H3, a B7 family member that modulates T cell and innate immune signaling and is also linked to cell-intrinsic programs in cancer biology. In human tissues, B7-H3 influences cytokine networks and immune checkpoint–like interactions, while affecting pathways associated with adhesion, migration, and survival signaling. Dysregulated CD276 expression is frequently observed across solid tumors and has been associated with immune evasion phenotypes and altered tumor microenvironment crosstalk. These properties make CD276 a useful target for mechanistic studies of immunomodulation and tumor-associated signaling circuits.

    B7-H3 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CD276 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CD276. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CD276 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.

    To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CD276-disrupted clones.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.